Literature DB >> 32084498

Structure-based view of the druggable genome.

Jiayan Wang1, Setayesh Yazdani1, Ana Han1, Matthieu Schapira2.   

Abstract

International efforts are underway to develop chemical probes for specific protein families, and a 'Target 2035' call to expand these efforts towards a comprehensive chemical coverage of the druggable human genome was recently announced. But what is the druggable genome? Here, we systematically review structures of proteins bound to drug-like ligands available from the Protein Data Bank (PDB) and use ligand desolvation upon binding as a druggability metric to draw a landscape of the human druggable genome. The vast majority of druggable protein families, including some highly populated and disease-associated families, are almost orphan of small-molecule ligands. We propose a list of 46 druggable domains representing 3440 human proteins that could be the focus of large chemical probe discovery efforts.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32084498     DOI: 10.1016/j.drudis.2020.02.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  6 in total

Review 1.  The PROTACtable genome.

Authors:  Melanie Schneider; Chris J Radoux; Andrew Hercules; David Ochoa; Ian Dunham; Lykourgos-Panagiotis Zalmas; Gerhard Hessler; Sven Ruf; Veerabahu Shanmugasundaram; Michael M Hann; Pam J Thomas; Markus A Queisser; Andrew B Benowitz; Kris Brown; Andrew R Leach
Journal:  Nat Rev Drug Discov       Date:  2021-07-20       Impact factor: 84.694

2.  Nuclear Receptor Chemical Reporter Enables Domain-Specific Analysis of Ligands in Mammalian Cells.

Authors:  Taku Tsukidate; Qiang Li; Howard C Hang
Journal:  ACS Chem Biol       Date:  2020-09-10       Impact factor: 5.100

3.  Molecular mechanism of interaction between fatty acid delta 6 desaturase and acyl-CoA by computational prediction.

Authors:  Jie Cui; Haiqin Chen; Xin Tang; Hao Zhang; Yong Q Chen; Wei Chen
Journal:  AMB Express       Date:  2022-06-09       Impact factor: 4.126

4.  A novel screening strategy to identify histone methyltransferase inhibitors reveals a crosstalk between DOT1L and CARM1.

Authors:  Yang Si; Corentin Bon; Magdalena Barbachowska; Veronique Cadet-Daniel; Corinne Jallet; Laura Soresinetti; Mikaël Boullé; Magalie Duchateau; Mariette Matondo; Fabrice Agou; Ludovic Halby; Paola B Arimondo
Journal:  RSC Chem Biol       Date:  2022-02-22

5.  Prioritization of Molecular Targets for Antimalarial Drug Discovery.

Authors:  Barbara Forte; Sabine Ottilie; Andrew Plater; Brice Campo; Koen J Dechering; Francisco Javier Gamo; Daniel E Goldberg; Eva S Istvan; Marcus Lee; Amanda K Lukens; Case W McNamara; Jacquin C Niles; John Okombo; Charisse Flerida A Pasaje; Miles G Siegel; Dyann Wirth; Susan Wyllie; David A Fidock; Beatriz Baragaña; Elizabeth A Winzeler; Ian H Gilbert
Journal:  ACS Infect Dis       Date:  2021-09-15       Impact factor: 5.084

6.  Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs.

Authors:  Atsushi Hijikata; Clara Shionyu-Mitsuyama; Setsu Nakae; Masafumi Shionyu; Motonori Ota; Shigehiko Kanaya; Tsuyoshi Shirai
Journal:  FEBS Lett       Date:  2020-05-25       Impact factor: 3.864

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.